|
Henry J. Fuchs, M.D., joined Onyx in September 2005 as Executive Vice President and Chief Medical Officer. Previously Dr. Fuchs was chief executive officer of IntraBiotics, a biotechnology company. He originally joined IntraBiotics in 1996 as vice president of clinical affairs before assuming the role of president and chief operating officer in 2001. From 1987 to 1996, Dr. Fuchs was employed by Genentech where he held a number of positions of increasing responsibility. While there he led the clinical team that played an integral role in the approval of Herceptin, a breast cancer treatment, as well as Pulmozyme, a therapeutic for cystic fibrosis. Dr. Fuchs earned an M.D. degree from George Washington University and a B.A. in biochemical sciences from Harvard College. Dr. Fuchs serves on the board of IntraBiotics. | 